NEW YORK (GenomeWeb News) — The European Molecular Biology Laboratory has signed a license for two of Tripos' software platforms for use in its chemical biology research, the company said today.

The agreement covers Tripos' ligand-receptor docking and virtual screening software, the Surflex-Dock, and its Themis software for use in drug discovery research.

EMBL will use the software in research at the Chemical Biological Core Facility, which is a collaboration between EMBL and the German Cancer Research Center in Heidelberg and the University of Heidelberg.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

Jun
23
Sponsored by
PerkinElmer

This webinar will demonstrate how automated liquid handling workstations can reduce bottlenecks in library preparation for next-generation sequencing, enabling scientific advances in genomics research that were not possible five years ago.